Verschoor E J, Mooij P, Oostermeijer H, van der Kolk M, ten Haaft P, Verstrepen B, Sun Y, Morein B, Akerblom L, Fuller D H, Barnett S W, Heeney J L
Department of Virology, Biomedical Primate Research Center, Rijswijk, The Netherlands.
J Virol. 1999 Apr;73(4):3292-300. doi: 10.1128/JVI.73.4.3292-3300.1999.
The kinetics of T-helper immune responses generated in 16 mature outbred rhesus monkeys (Macaca mulatta) within a 10-month period by three different human immunodeficiency virus type 1 (HIV-1) vaccine strategies were compared. Immune responses to monomeric recombinant gp120SF2 (rgp120) when the protein was expressed in vivo by DNA immunization or when it was delivered as a subunit protein vaccine formulated either with the MF59 adjuvant or by incorporation into immune-stimulating complexes (ISCOMs) were compared. Virus-neutralizing antibodies (NA) against HIV-1SF2 reached similar titers in the two rgp120SF2 protein-immunized groups, but the responses showed different kinetics, while NA were delayed and their levels were low in the DNA-immunized animals. Antigen-specific gamma interferon (IFN-gamma) T-helper (type 1-like) responses were detected in the DNA-immunized group, but only after the fourth immunization, and the rgp120/MF59 group generated both IFN-gamma and interleukin-4 (IL-4) (type 2-like) responses that appeared after the third immunization. In contrast, rgp120/ISCOM-immunized animals rapidly developed marked IL-2, IFN-gamma (type 1-like), and IL-4 responses that peaked after the second immunization. To determine which type of immune responses correlated with protection from infection, all animals were challenged intravenously with 50 50% infective doses of a rhesus cell-propagated, in vivo-titrated stock of a chimeric simian immunodeficiency virus-HIVSF13 construct. Protection was observed in the two groups receiving the rgp120 subunit vaccines. Half of the animals in the ISCOM group were completely protected from infection. In other subunit vaccinees there was evidence by multiple assays that virus detected at 2 weeks postchallenge was effectively cleared. Early induction of potent type 1- as well as type 2-like T-helper responses induced the most-effective immunity.
比较了三种不同的1型人类免疫缺陷病毒(HIV-1)疫苗策略在10个月内使16只成熟的远交恒河猴(猕猴)产生的辅助性T细胞免疫反应的动力学。比较了通过DNA免疫在体内表达单体重组gp120SF2(rgp120)蛋白时,以及将其作为与MF59佐剂配制的亚单位蛋白疫苗或掺入免疫刺激复合物(ISCOM)中递送时,对单体重组gp120SF2的免疫反应。在两个接受rgp120SF2蛋白免疫的组中,针对HIV-1SF2的病毒中和抗体(NA)达到了相似的滴度,但反应显示出不同的动力学,而在DNA免疫的动物中,NA延迟出现且水平较低。在DNA免疫组中检测到了抗原特异性γ干扰素(IFN-γ)辅助性T细胞(1型样)反应,但仅在第四次免疫后出现,而rgp120/MF59组在第三次免疫后产生了IFN-γ和白细胞介素-4(IL-4)(2型样)反应。相比之下,接受rgp120/ISCOM免疫的动物迅速产生了明显的IL-2、IFN-γ(1型样)和IL-4反应,这些反应在第二次免疫后达到峰值。为了确定哪种类型的免疫反应与预防感染相关,所有动物均静脉注射50个50%感染剂量的恒河猴细胞增殖的、体内滴定的嵌合猿猴免疫缺陷病毒-HIVSF13构建体毒株。在接受rgp120亚单位疫苗的两个组中观察到了保护作用。ISCOM组中有一半的动物完全免受感染。在其他亚单位疫苗接种动物中,通过多种检测方法有证据表明在攻击后2周检测到的病毒被有效清除。早期诱导有效的1型以及2型样辅助性T细胞反应可诱导最有效的免疫。